Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058830 | 0.87 | HSD17B1 (0.50) | MEN1KMT2AHSD17B1HSD17B2S1PR1 | |
| SCHEMBL3047557 | 0.85 | KMO (0.52) | MEN1KMT2AHSD17B1HSD17B2S1PR1 | |
| SCHEMBL13139532 | 0.82 | MEN1 (0.47) | MEN1KMT2AHSD17B1HSD17B2S1PR1 | |
| SCHEMBL27421833 | 0.81 | MEN1 (0.55) | MEN1KMT2AHSD17B1HSD17B2S1PR1 | |
| SCHEMBL3051446 | 0.81 | S1PR1 (0.44) | MEN1KMT2AHSD17B1HSD17B2S1PR1 | |
| SCHEMBL13139523 | 0.81 | MEN1 (0.46) | MEN1KMT2AHSD17B1HSD17B2S1PR1 | |
| SCHEMBL3057526 | 0.80 | ALDH1A1 (0.43) | MEN1KMT2AHTR6ALDH1A1NTSR1 | |
| SCHEMBL27422020 | 0.79 | MEN1 (0.57) | MEN1KMT2AHSD17B1HSD17B2S1PR1 | |
| SCHEMBL3063587 | 0.78 | SLC22A12 (0.48) | HTR6NTSR1 | |
| SCHEMBL3056950 | 0.69 | HTR2C (0.48) | ALDH1A1HSD17B10NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222324-A1 | Substituted Indole Compounds | BDKRB1, BDKRB2, EDNRB | MEN1 1256/4885KMT2A 2512/4885HSD17B1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.